Consensus Evolus, Inc.

Stocks

EOLS

US30052C1071

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-20 EDT			5-day change	1st Jan Change
5.545 ^USD	-3.23%		-16.11%	-16.62%

07-08	Evolus Enters Exclusive Licensing and Distribution Agreement with Ibsa to Develop and Commercialize Profhilo in the United States	CI
07-08	Evolus Partners With IBSA to Develop, Commercialize Profhilo in US	MT

Evolution of the Average Target: Evolus, Inc.

Evolution of the Target Price: Evolus, Inc.

Changes in Analyst Recommendations: Evolus, Inc.

43bea5cae53bc4f32648ea8ddd.OXN8px3F5HmK9RxmXg-MxweKNH1jGMYpFe53o6l8AB0.bSw90CuVlTzCmU4fClzArUjeDUouc4hzc5k7--MNWkJcA0XjW6GMGPOPWQ~d8aac72d0dec42d015427cb2e5ce46ec

Analysts' recommendations: Evolus, Inc.

11-12	Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025	CI
25-04-17	BTIG Initiates Evolus at Buy With $21 Price Target	MT
24-03-08	Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating	MT
24-01-29	Barclays Upgrades Evolus to Overweight From Equalweight, Raises Price Target to $16 From $10	MT
23-08-03	HC Wainwright Adjusts Price Target on Evolus to $27 From $16, Maintains Buy Rating	MT
23-06-07	Mizuho Securities Adjusts Evolus Price Target to $20 From $17, Maintains Buy Rating	MT
23-05-26	Truist Securities Adjusts Price Target on Evolus to $18 From $14, Maintains Buy Rating	MT
23-05-10	HC Wainwright Adjusts Price Target on Evolus to $16 From $15, Maintains Buy Rating	MT
23-01-19	Mizuho Securities Adjusts Evolus' Price Target to $17 From $15, Keeps Buy Rating	MT
22-06-23	Needham & Co Initiates Coverage on Evolus With Buy Rating, $18 Price Target	MT
22-05-12	Barclays Upgrades Evolus to Equalweight From Underweight, Adjusts Price Target to $10 From $8	MT
22-01-20	Truist Securities Upgrades Evolus to Buy From Hold; Price Target is $11	MT
21-11-03	HC Wainwright Adjusts Evolus' Price Target to $15 From $22, Keeps Buy Rating	MT
21-05-13	EVOLUS : Barclays Adjusts Evolus' Price Target to $7 From $8, Maintains Underweight Rating	MT
21-05-06	EVOLUS : Mizuho Securities Upgrades Evolus to Buy From Neutral; Price Target is $15	MT
21-04-08	EVOLUS : HC Wainwright Adjusts Evolus' Price Target to $22 From $20, Maintains Buy Rating	MT
21-03-30	EVOLUS : Mizuho Adjusts Evolus' Price Target to $15 From $9, Maintains Neutral Rating	MT
21-03-24	EVOLUS : HC Wainwright Adjusts Evolus' Price Target to $20 From $18, Maintains Buy Rating	MT
21-02-24	EVOLUS : Truist Securities Downgrades Evolus to Hold From Buy, Adjusts Price Target to $12 From $6	MT
21-02-22	EVOLUS : Barclays Adjusts Evolus' Price Target to $8 From $4, Reiterates Underweight Rating	MT
21-02-22	EVOLUS : Cantor Fitzgerald Adjusts Evolus' Price Target to $20 From $11, Maintains Overweight Rating	MT
21-02-22	EVOLUS : Mizuho Adjusts Evolus' Price Target to $9 From $5, Maintains Neutral Rating	MT
21-02-22	EVOLUS : HC Wainwright Adjusts Evolus' Price Target to $18 From $6, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EVOLUS, INC.					+155.96%
	ELI LILLY AND COMPANY					+7.74%
	JOHNSON & JOHNSON					+6.68%
	ABBVIE INC.					+4.75%
	ROCHE HOLDING AG					+7.49%
	NOVARTIS AG					-1.48%
	ASTRAZENECA PLC					+25.2%
	NOVO NORDISK A/S					-4.34%
	AMGEN INC.					-2.64%
	GILEAD SCIENCES, INC.					+17.89%
	Average					+21.72%
	Weighted average by Cap.					+6.87%